ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).

von Laffert, M

ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.). [electronic resource] - Lung cancer (Amsterdam, Netherlands) 01 2017 - 1-5 p. digital

Publication Type: Journal Article

1872-8332

10.1016/j.lungcan.2016.11.008 doi


Algorithms
Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung--genetics
Crizotinib
Disease Progression
Gene Rearrangement
Germany
Humans
Immunohistochemistry--methods
In Situ Hybridization, Fluorescence--methods
Lung Neoplasms--genetics
Oncogene Proteins, Fusion--genetics
Protein Kinase Inhibitors--therapeutic use
Pyrazoles--therapeutic use
Pyridines--therapeutic use
Receptor Protein-Tyrosine Kinases--genetics
Survival
Translocation, Genetic